PTX 0.00% 3.9¢ prescient therapeutics limited

Pitt St Research Report..., page-11

  1. 5,960 Posts.
    lightbulb Created with Sketch. 18458
    I believe that the preference has always been to use Cell-Pryme A as a neoadjuvant.

    According to the patent, Cell-Pryme A should be administered at least 18 hours prior to CAR-T, dendritic cells or NK cells being administered.

    https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022241515&_cid=P11-LP80EH-30307-1
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.